Clinical trials: Graft Function
Postoperative Graft Function
Hepatic Vein Flow During Orthotopic Liver Transplantation as Predictive Factor for Postoperative Graft Function
Hepatic vein flow (HVF) assessment using transesophageal echocardiography (TEE) has a potential to predict postoperative graft function in orthotopic liver transplant (OLT).
- Trial name
- NCT03814031
- Testing
- NO internvention
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Henry Ford Health System
Organ Transplantation
Remote Ischemic Preconditioning in Neurological Death Organ Donors
The purpose of this study is to determine whether application of lower limb remote ischemic preconditioning (RIPC) after determination of brain death improves donor stability, organ quality, organ yield, and early post transplant…
- Trial name
- RIPNOD (NCT01515072)
- Testing
- RIPC (Remote Ischemic Preconditioning)
- Where
- 2 sites in United States
- Volunteers
- 321 people
- Sponsor
- Rutgers, The State University of New Jersey
Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy.
- Trial name
- NCT02350777
- Testing
- Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Graft-Versus-Host Disease
Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease
This study is designed to collect longitudinal biological samples from patients after hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers to validate biomarkers of both acute and chronic…
- Trial name
- NCT02194439
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Indiana University
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Diseases, Non-malignant Diseases
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor.
- Trial name
- NCT02162511
- Testing
- CliniMACS CD34+ cell enrichment and T-cell depletion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rajni Agarwal
Function of Renal Transplant
Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
The aim of this study is to evaluate whether peri-transplant administration of a drug named aminophylline to children undergoing a kidney transplant from deceased donors improves early graft function and also projects on long…
- Trial name
- RTphylline (NCT01759862)
- Testing
- Aminophylline, Theophylline drug levels
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Waning Donor Chimerism, Waning Immune Function
CD34+ Stem Cell Infusion to Augment Graft Function
The purpose of this study is to determine if infusing additional special donor cells will help to improve graft or immune function in previously transplanted children with immune deficiencies and bone marrow failures.
- Conditions
- Waning Donor Chimerism, Waning Immune Function, Primary Immunodeficiency Disease(s), Bone Marrow Failure
- Trial name
- NCT01856582
- Testing
- CD34+
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Poor Graft Function
Decitabine for Poor Graft Function Post Allo-HSCT
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
- Trial name
- NCT05907499
- Testing
- Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist
- Where
- China
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University